From: Pancreatic cancer genomics: insights and opportunities for clinical translation
Agent | Patients targeted | Median overall survival | References |
---|---|---|---|
Mitomycin Ca | Patients with mutations in PALB2 | - | [61] |
Olapariba | Patients with mutations in BRCA2 | - | |
Gemcitabine alone | All | 5.65-7.2 monthsb | |
Gemcitabine + cisplatin | All | 7.5 months | [91] |
Gemcitabine + erlotinib | All | 6.2 months | [10] |
Gemcitabine + capecitabine | All | 7.1-8.4 monthsb | |
Gemcitabine + docetaxel + capecitabine (GTX)a | All | - | [95] |
Gemcitabine + Nab-paclitaxel | All | 12.2 months | [11] |
Folinic acid + fluorouracil + irinotecan + oxaliplatin (FOLFIRINOX) | All | 11.1 months | [90] |